Current Report Filing (8-k)
September 13 2021 - 08:02AM
Edgar (US Regulatory)
0001535955 false 0001535955 2021-09-13
2021-09-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported):
September 13, 2021
LIPOCINE INC.
(Exact name
of registrant as specified in its charter)
Commission
File No.
001-36357
|
Delaware |
|
99-0370688 |
|
(State or other
jurisdiction
of
incorporation)
|
|
(IRS Employer
Identification
Number)
|
675 Arapeen Drive,
Suite 202
Salt Lake City,
Utah
84108
(Address of
principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(801)
994-7383
Former name
or former address, if changed since last report: Not
Applicable
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
I Securities
registered pursuant to Section 12(b) of the
Act:
|
Title of
each class |
|
Trading
Symbol(s) |
|
Name of each
exchange on which registered |
|
Common Stock, par value $0.0001 per share |
|
LPCN |
|
The
NASDAQ Stock Market LLC |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR § 240.12b-2).
Emerging
growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01
Other Events
The Company
has updated its corporate presentation that it uses when meeting
with investors, analysts and others. The presentation is filed as
Exhibit 99.1.
Item 9.01
Financial Statements and Exhibits.
The
following exhibits are filed with this report:
|
Exhibit
No. |
|
Description |
|
99.1
|
|
Corporate Presentation
|
| 104 |
|
Cover Page
Interactive Data File (embedded within the Inline XBRL
document) |
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
|
|
LIPOCINE
INC. |
|
|
|
|
|
|
|
Date: |
September
13, 2021 |
|
By: |
/s/
Mahesh V. Patel |
| |
|
|
|
Mahesh V.
Patel |
| |
|
|
|
President and Chief
Executive Officer |
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2022 to May 2022
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From May 2021 to May 2022
